Form D · Pharmaceuticals

Sermonix Pharmaceuticals, Inc.

Columbus, OH · CIK 0001655566

Offering snapshot reported Nov 23, 2021 · SEC filing

Reported sold
$40.2M
Offering amount: $40.2M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 12, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 23, 2021Initial$40,225,000No comparison9SEC filing
Jul 11, 2016Initial$1,550,000No comparison2SEC filing
Oct 14, 2015Initial$1,020,000No comparison17SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$2.22M
Finders' fees
$0
Form D file number
021-422178

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
LIFESCI CAPITAL168404

Source: Form D, filed Nov 23, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Elizabeth Attias Executive
Richard De Schutter Director
Michael Friedman Director
Elizabeth Garner Director
Simon Jenkins Executive
Barry Komm Executive
Thomas Pfisterer Director
Paul Plourde Executive
Miriam Portman Executive, Promoter
David Portman Director, Executive, Promoter
Patrick Wiesel Director
Anthony Wild Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
3000 E. Main St
Columbus, OH, 43209